Advertising

Clinical
Volume 54, Issue 4, April 2025

A refresher on the primary care and public health management of acute post-streptococcal glomerulonephritis

Jasraaj Singh    Allison Hempenstall    Melania Scrace    Louise Craig    Malcolm McDonald   
doi: 10.31128/AJGP-03-24-7206   |    Download article
Cite this article    BIBTEX    REFER    RIS

Background

Acute post-streptococcal glomerulonephritis (APSGN) is an acute autoimmune kidney condition triggered by skin infection or pharyngitis caused by specific strains of Streptococcus pyogenes (Group A streptococcus). In Australia, APSGN is primarily a disease of childhood disadvantage.

Objective
The aim of this review is to draw attention to a preventable childhood condition, detailing the clinical presentation, diagnostic pathway and management.
Discussion

Children typically present with a nephritic clinical picture: oedema, painless haematuria and hypertension. Diagnostic confirmation requires specific laboratory findings or both clinical and laboratory suggestive evidence. ‘Probable’ cases only require clinical evidence and ‘possible’ cases only require suggestive laboratory evidence. Treatment is largely supportive, focusing on the management of hypertension and fluid overload. Suspected and confirmed cases must be notified immediately to regional public health authorities. Outbreaks require a broad-based public health response in accordance with state-based guidelines.

 

In Australia, acute post-streptococcal glomerulonephritis (APSGN) is primarily a disease of childhood disadvantage. It is an acute autoimmune kidney condition that is triggered by skin infection (impetigo/pyoderma) or pharyngitis due to nephritogenic strains of Streptococcus pyogenes (Group A streptococcus [Strep A]).1 The peak age group for APSGN is 5–14 years.

The documented incidence of APSGN is strikingly higher among Aboriginal and Torres Strait Islander people (more than 170 cases per 100,000 population/year compared to the national figure of 11 per 100,000 population/year) than among non-Indigenous Australians.2–4 Aboriginal and Torres Strait Islander children, especially in regional and remote settings, carry an inequitable burden of Strep A disease compared with non-Indigenous Australians.5 As such, in high-risk communities, there is usually a background of sporadic disease with intermittent broader outbreaks.2,6,7

The diagnosis of APSGN can be elusive; this is a diagnostic hurdle. It is estimated that up to 75% of cases of APSGN are subclinical and go undetected because of few or no symptoms.8 In the 1993 Far North Queensland impetigo-driven outbreak, only one-third of children with APSGN were symptomatic; the rest were only detected through community screening.6 Even when there are symptoms, children might not present to the clinic. We already know that in some remote settings, childhood Strep A skin infection is often normalised; it frequently goes unrecognised and untreated.9

Aim

The aim of this brief review is to draw attention to an often-missed critical and preventable childhood condition, detailing the clinical presentation, diagnostic pathway and management of APSGN.

Clinical presentation

Children typically present with a nephritic clinical picture: oedema, painless haematuria and hypertension (Table 1).1 However, it is not always that easy; these features might not manifest together at the same time. In the case of Aboriginal and Torres Strait Islander children, a family member often brings a child into the clinic because of new-onset facial swelling.7

Table 1. Symptoms of and risk factors for acute post-streptococcal glomerulonephritis
Symptoms Risk factors
Haematuria Poverty
Hypertension Household crowding
Facial and/or peripheral oedema Previous APSGN diagnosis
APSGN, acute post-streptococcal glomerulonephritis.

Periorbital oedema is also a feature of nephritic syndrome and occurs in approximately two-thirds of symptomatic patients with APSGN.7,10 Macroscopic haematuria is the other common presentation, and many cases are discovered incidentally from routine urine analysis.

Hypertension (adjusted for age and height) is usually an asymptomatic finding and can persist for several weeks, or even for months. Serial blood pressure readings might also need to be done outside the clinic setting because some children might have ‘white coat hypertension’. Clinicians should measure a child’s height to determine whether their blood pressure is over the 95th percentile for their sex, age and height (Box 1; Table 2). Additional symptoms can include anorexia, malaise, nausea and even vomiting.10

Box 1. Best practice principles of hypertension diagnosis
  • Three different blood pressure measures averaged
  • The use of appropriately sized cuffs
  • Correct patient positioning
  • The use of auscultation for at least one measure
  • Determined against tables based on age and height to be above the 95th percentile20
   
Table 2. Systolic blood pressure values (95th percentile) for children according to their sex, age and height as per the American Academy of Pediatrics20
95th SBP percentile for males (left) and females (right) by age and height
Age (years) BP percentile SBP (mmHg) SBP (mmHg)
Measured height Measured height
1 Height (cm)  77.2  78.3  80.2  82.4  84.6  86.7  87.9  75.4  76.6  78.6  80.8  83  84.9  86.1 
95th  102  102  103  103  104  105  105  101  102  102  103  104  105  105 
2 Height (cm)  86.1  87.4  89.6  92.1  94.7  97.1  98.5  84.9  86.3  88.6  91.1  93.7  96  97.4 
95th  104  105  105  106  107  107  108  104  105  106  106  107  108  109 
3 Height (cm)  92.5  93.9  96.3  99  101.8  104.3  105.8  91  92.4  94.9  97.6  100.5  103.1  104.6 
95th 106  106  107  107  108  109  109  106  106  107  108  109  110  110 
4 Height (cm)  98.5  100.2  102.9  105.9  108.9  111.5  113.2  97.2  98.8  101.4  104.5  107.6  110.5  112.2 
95th  107  107  108  108  109  110  110  107  108  109  109  110  111  112 
5 Height (cm)  104.4  106.2  109.1  112.4  115.7  118.6  120.3  103.6  105.3  108.2  111.5  114.9  118.1  120 
95th  107  108  109  109  110  111  112  108  109  109  110  111  112  113 
6 Height (cm)  110.3  112.2  115.3  118.9  122.4  125.6  127.5  110  111.8  114.9  118.4  122.1  125.6  127.7 
95th  108  109  110  111  112  113  114  109  109  110  111  112  113  114 
7 Height (cm)  116.1  118  121.4  125.1  128.9  132.4  134.5  115.9  117.8  121.1  124.9  128.8  132.5  134.7 
95th 110  110  111  112  114  115  116  109  110  111  112  113  114  115 
8 Height (cm)  121.4  123.5  127  131  135.1  138.8  141  121  123  126.5  130.6  134.7  138.5  140.9 
95th 111  112  112  114  115  116  117  110  111  112  113  115  116  117 
9 Height (cm)  126  128.3  132.1  136.3  140.7  144.7  147.1  125.3  127.6  131.3  135.6  140.1  144.1  146.6 
95th  112  112  113  115  116  118  119  112  112  113  114  116  117  118 
10 Height (cm)  130.2  132.7  136.7  141.3  145.9  150.1  152.7  129.7  132.2  136.3  141  145.8  150.2  152.8 
95th  112  113  114  116  118  120  121  113  114  114  116  117  119  120 
11 Height (cm)  134.7  137.3  141.5  146.4  151.3  155.8  158.6  135.6  138.3  142.8  147.8  152.8  157.3  160 
95th  114  114  116  118  120  123  124  115  116  117  118  120  123  124 
12 Height (cm)  140.3  143  147.5  152.7  157.9  162.6  165.5  142.8  145.5  149.9  154.8  159.6  163.8  166.4 
95th  116  117  118  121  124  126  128  118  119  120  122  124  125  126 
13 Height (cm)  147  150  154.9  160.3  165.7  170.5  173.4  148.1  150.6  154.7  159.2  163.7  167.8  170.2 
95th  119  120  122  125  128  130  131  121  122  123  124  126  126  127 
14 Height (cm)  153.8  156.9  162  167.5  172.7  177.4  180.1  150.6  153  156.9  161.3  165.7  169.7  172.1 
95th  123  125  127  130  132  133  134  123  123  124  125  126  127  127 
15 Height (cm)  159  162  166.9  172.2  177.2  181.6  184.2  151.7  154  157.9  162.3  166.7  170.6  173 
95th  127  129  131  132  134  135  135  124  124  125  126  127  127  128 
16 Height (cm)  162.1  165  169.6  174.6  179.5  183.8  186.4  152.1  154.5  158.4  162.8  167.1  171.1  173.4 
95th  130  131  133  134  135  136  137  124  125  125  127  127  128  128 
17 Height (cm)  163.8  166.5  170.9  175.8  180.7  184.9  187.5  152.4  154.7  158.7  163.0  167.4  171.3  173.7 
  95th  132  133  134  135  137  138  138  125  125  126  127  128  128  128 
BP, blood pressure; SBP, systolic blood pressure.

The first challenge for the clinician is to think of APSGN. Of course, APSGN also occurs in non-Aboriginal and Torres Strait Islander people and, here, the diagnosis might be even more difficult because of a low index of suspicion. Thus, the initial community clinical assessment should include close inspection for oedema, careful blood pressure measurement and a urine dipstick/urinalysis test.

The background history is critical. APSGN usually occurs approximately four weeks after the onset of impetigo and two weeks after Strep A pharyngitis.10 However, some patients might also have active impetigo when APSGN develops. When patients develop APSGN without clear preceding impetigo or symptomatic pharyngitis, it can be diagnostically challenging.11

A household history is also essential. How many people live in the house? Have there been episodes of skin sores or periods of sore throat recently? Is there a household history of APSGN? High community and household burdens of Strep A infection tend to occur in the setting of poverty, household crowding, scabies infections and poor health literacy.1 In the 2005 Far North Queensland APSGN outbreak, almost half the otherwise healthy 87 children (aged 2–12 years) screened in the community had infected skin sores, and all had scabies.7 APSGN tends to run in households and families, but this is almost certainly environmental rather than due to genetic susceptibility.

Investigations

When a general practitioner suspects APSGN, the diagnosis must be confirmed. This requires several key investigations (Box 2). Patients with a positive urine dipstick/urinalysis with 2+ or more red blood cells (RBC) in the urine should have samples sent away for microscopy, culture and sensitivity (MCS). Occasional false-positive urine dipstick results necessitate laboratory confirmation with haematuria of >10 RBC/µL.

Box 2. Investigations required to diagnose acute post-streptococcal glomerulonephritis8
  • Urine microscopy, culture and sensitivity
  • Urea, electrolytes and creatine
  • C3 and C4 complement
  • Anti-streptolysin O titre
  • Anti-DNase B
  • Throat and/or skin swab microscopy, culture and sensitivity

Clinicians are advised to check serum urea, electrolytes and creatinine. Urea and creatinine might be elevated during the acute phase of the inflammatory process. If raised, clinicians are advised to monitor closely and seek specialist advice.8 In most children, they resolve after several weeks.

Evidence of a recent Strep A infection can be determined by an elevated or rising anti-streptolysin titre (ASOT), an elevated anti-DNase B titre, recovery of Strep A from the throat or skin sore or a positive Strep A antigen test.8,12,13 Across rural and remote Australia, these tests might take a week or more to return to the clinic.

Diagnosis

The diagnosis of APSGN can be complicated. Cases of ASPGN can be categorised as ‘confirmed’, ‘probable’ and ‘possible’ on the basis of both available clinical and laboratory evidence (Box 3). ‘Confirmed’ cases require either definitive laboratory evidence or both suggestive clinical and laboratory evidence. ‘Probable’ cases only require clinical evidence and ‘possible’ cases only require suggestive laboratory evidence. These criteria differ somewhat between states and territories in Australia, so if in doubt it is best to check your local guidelines.8,12,13 All cases, regardless of categorisation, require prompt treatment. We should not wait for all the laboratory results to return.

Box 3. Evidence required to diagnose acute post-streptococcal glomerulonephritis12
Laboratory definitive evidence
  • Renal biopsy suggestive of acute post-streptococcal glomerulonephritis
Laboratory suggestive evidence (all three criteria must be met)
  • Haematuria on microscopy (red blood cells >10/µL)
  • Evidence of recent Group A streptococcus infection (elevated anti-streptolysin O titre or anti-DNase B or positive Group A streptococcus on skin/throat culture)
  • Reduced C3 level
Clinical evidence (at least two of the three criteria must be met)
  • Facial and/or peripheral oedema
  • Moderate haematuria
  • Hypertension, according to age/sex and height percentiles

Management

Approximately two-thirds of children with APSGN can be managed in the community, but approximately one-third will require hospitalisation. Adults with new-onset APSGN tend to have much more severe and prolonged disease and should be referred to the emergency department for further work-up and management. Patients who are managed in remote settings require careful follow-up and distant advice from experienced paediatricians or physicians experienced in APSGN management. Hospitalisation is indicated when hypertension and/or fluid overload cannot be controlled in the community.14

In all cases of suspected APSGN, patients should be given intramuscular benzathine benzylpenicillin to eradicate any Strep A. However, this does not alter the autoimmune process (Table 3). Intramuscular benzathine benzylpenicillin is a painful injection that must only be given by someone properly trained and skilled in the procedure.15 If the patient with suspected APSGN is allergic to penicillin, they should receive oral trimethoprim and sulfamethoxazole as per the Australian Therapeutic Guidelines (eTG).13,16 The management of any child whose systolic blood pressure is greater than the 95th percentile for sex, age and height should be promptly discussed with a paediatrician. An antihypertensive agent will probably be required and will be selected based on the patient’s clinical and fluid status.

Table 3. Intramuscular benzathine benzylpenicillin weight-based dosing21
Weight Dose
<10 kg 450,000 IU
10–20 kg 600,000 IU
>20 kg 1,200,000 IU

The covering paediatrician will help with follow-up. This might include weekly blood pressure and urine dipstick checks for six to eight weeks after presentation. Most children with APSGN tend to clinically recover over about six weeks. Macroscopic haematuria, hypertension and low C3 usually also normalise within 6–8 weeks. However, microscopic haematuria can persist for up to two years.10 If there is persistent haematuria and/or hypertension and/or proteinuria and/or kidney function impairment, patients should be followed up at least until these manifestations have completely resolved. There is evolving evidence to suggest that it might be best to follow children with APSGN into adulthood. At the present time, it is impossible to assess and monitor any subtle glomerular injuries left behind, but we now know they have an impact later in life.17 Early intervention is needed to improve the chances of preventing APSGN-related chronic kidney disease.17

Public health implications

General practitioners are encouraged to notify their local public health service immediately whenever they encounter a suspected case of APSGN, even before the confirmatory tests results have become available. As of 2024, APSGN is notifiable in the Northern Territory, Western Australia and, more recently, Queensland.8,12,13

Confirmed and probable APSGN cases require household contact tracing. All individuals living in the house over the two weeks prior to symptom onset (or positive laboratory tests) need to be assessed for skin sores, sore throats, scabies, hypertension, oedema and haematuria. In addition, the family, household and close contacts of a confirmed APSGN patient who have stayed in the household in the two weeks preceding the onset of APSGN require treatment.13 Intramuscular LA Bicillin (benzathine benzylpenicillin) must be administered to all contacts aged between one and 17 years and all adults aged 17 years and over who have skin sores.13

When a public health unit declares an outbreak, as determined by local guidelines, the primary aim is to reduce Strep A transmission and prevent further cases of APSGN. This involves screening all children aged between one and 17 years, as above, followed by appropriate management. This public health response requires close partnerships with local primary healthcare facilities and community leaders.18

When there is an outbreak, Strep A cultured from cases or contacts will be sent to a reference laboratory and genotyped to determine the M protein gene (emm) type. The villain or villains might turn out to be well-known nephritogenic strains, such as emm type 55, or even newly recognised strains.19

Prevention

The prevention of Strep A requires well-resourced health promotion programs and annual health checks in communities at risk. This requires a strengths-based approach, led by Aboriginal and Torres Strait Islander health workers based in the community. Until the primordial causative factors for APSGN (poverty and a lack of housing, employment and health education) are addressed by the wider community, there are no other viable preventative mechanisms.

Key points

  • APSGN is largely unrecognised and undetected.
  • APSGN is primarily a disease of childhood disadvantage. APSGN in adults is relatively rare, but usually more severe. The diagnosis of APSGN is guided by a clear set of criteria.
  • Although there appears to be early clinical recovery (>90%), childhood APSGN is a strong risk factor for chronic kidney disease in later life.
  • Treatment is largely supportive, with a focus on hypertension and fluid overload. Prevention of APSGN at the community level requires eternal vigilance.
  • Suspected and confirmed cases of APSGN must be notified immediately to regional public health authorities.
  • Outbreaks of APSGN require a broad-based public health response in accordance with state-based guidelines.
Competing interests: None.
Provenance and peer review: Not commissioned, externally peer reviewed.
Funding: None.
Correspondence to:
jasraaj.singh@health.qld.gov.au
Acknowledgements
The authors sincerely thank Dr Alan Ruben for valuable insights into APSGN that contributed to this article.
This event attracts CPD points and can be self recorded

Did you know you can now log your CPD with a click of a button?

Create Quick log
References
  1. Brant Pinheiro SV, de Freitas VB, de Castro GV, et al. Acute post-streptococcal glomerulonephritis in children: A comprehensive review. Curr Med Chem 2022;29(34):5543–59. doi: 10.2174/0929867329666220613103316. Search PubMed
  2. Chaturvedi S, Boyd R, Krause V. Acute post-streptococcal glomerulonephritis in the Northern Territory of Australia: A review of data from 2009 to 2016 and comparison with the literature. Am J Trop Med Hyg 2018;99(6):1643–48. doi: 10.4269/ajtmh.18-0093. Search PubMed
  3. Dowler J, Wilson A. Acute post-streptococcal glomerulonephritis in Central Australia. Aust J Rural Health 2020;28(1):74–80. doi: 10.1111/ajr.12568. Search PubMed
  4. Graham L, Neville J, Richards A, Fisher V, Taunton C, Hempenstall A. Improving public health surveillance systems for acute post-streptococcal glomerulonephritis in Far North Queensland, Australia. Popul Med 2023;5 Supplement:A1942. [Abstract] doi: 10.18332/popmed/163897. Search PubMed
  5. May PJ, Bowen AC, Carapetis JR. The inequitable burden of Group A streptococcal diseases in Indigenous Australians. Med J Aust 2016;205(5):201–03. doi: 10.5694/mja16.00400. Search PubMed
  6. Streeton CL, Hanna JN, Messer RD, Merianos A. An epidemic of acute post-streptococcal glomerulonephritis among Aboriginal children. J Paediatr Child Health 1995;31(3):245–48. doi: 10.1111/j.1440-1754.1995.tb00795.x. Search PubMed
  7. Scrace M, Koko K. An outbreak of acute post-streptococcal glomerulonephritis in remote Far North Queensland. Aust J Rural Health 2006;14(4):160–63. doi: 10.1111/j.1440-1584.2006.00795.x. Search PubMed
  8. Surveillance and Response Unit Communicable Disease Control. Public health management of acute post-streptococcal glomerulonephritis (APSGN). Northen Territory Health, 2024. Available at https://digitallibrary.health.nt.gov.au/entities/publication/16a3b91e-02e4-4480-ae6c-29fe16b7a496/details [Accessed 23 June 2024]. Search PubMed
  9. Davidson L, Knight J, Bowen AC. Skin infections in Australian Aboriginal children: A narrative review. Med J Aust 2020;212(5):231–37. doi: 10.5694/mja2.50361. Search PubMed
  10. Chong HC, Hung TY, Hohls A, Francis JR, Chaturvedi S. Clinical characteristics of hospitalised children with acute post-streptococcal glomerulonephritis in the Top End of Australia. J Paediatr Child Health 2023;59(5):735–42. doi: 10.1111/jpc.16386. Search PubMed
  11. Rawla P, Padala SA, Ludhwani D. Poststreptococcal glomerulonephritis. Updated 2022. StatPearls Publishing, 2024. Available at www.ncbi.nlm.nih.gov/books/NBK538255 [Accessed 23 July 2024]. Search PubMed
  12. Queensland Health. Acute post-steptococcal glomerulonephritis (APSGN). Queensland Health Guidelines for Public Health Units. Queensland Government, 2024. Available at www.health.qld.gov.au/cdcg/index/acute-post-streptococcal-glomerulonephritis-apsgn [Accessed 11 July 2024]. Search PubMed
  13. Government of Western Australia WA Country Health Service. Acute post-streptococcal glomerulonephritis guideline. Kimberley Public Health Guidelines, 2018. Available at www.wacountry.health.wa.gov.au/~/media/WACHS/Documents/About-us/Policies/Public-Health-Management-of-Acute-Post-Streptococcal-Glomerulonephritis-Guideline.pdf [Accessed 23 July 2024]. Search PubMed
  14. Steer AC, Danchin MH, Carapetis JR. Group A streptococcal infections in children. J Paediatr Child Health 2007;43(4):203–13. doi: 10.1111/j.1440-1754.2007.01051.x. Search PubMed
  15. Ong LT. Management and outcomes of acute post-streptococcal glomerulonephritis in children. World J Nephrol 2022;11(5):139–45. doi: 10.5527/wjn.v11.i5.139. Search PubMed
  16. Therapeutic Guidelines. Antibiotics. Therapeutic Guidelines, 2024. Available https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Antibiotic&topicfile=sore-throat&guidelinename=Antibiotic§ionId=toc_d1e47#toc_d1e47 [Accessed 7 October 2024]. Search PubMed
  17. Hoy WE, White AV, Dowling A, et al. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kidney Int 2012;81(10):1026–32. doi: 10.1038/ki.2011.478. Search PubMed
  18. Miller KM, Van Beneden C, McDonald M, et al. Standardization of epidemiological surveillance of acute poststreptococcal glomerulonephritis. Open Forum Infect Dis 2022;9 Suppl 1:S57–64. doi: 10.1093/ofid/ofac346. Search PubMed
  19. Worthing KA, Lacey JA, Price DJ, et al. Systematic review of group A streptococcal emm types associated with acute post-streptococcal glomerulonephritis. Am J Trop Med Hyg 2019;100(5):1066–70. doi: 10.4269/ajtmh.18-0827. Search PubMed
  20. Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017;140(3):e20171904. doi: 10.1542/peds.2018-1739. Search PubMed
  21. Queensland Health. Primary clinical care manual. 8. Paediatrics. 11th edn. Queensland Government, 2022. Available at www.health.qld.gov.au/__data/assets/pdf_file/0015/1215033/8.Paediatrics.pdf [Accessed 11 July 2024]. Search PubMed

Kidney diseasePublic health

Download article